Total Peripheral Lymphocyte Count in Malignant Tumors: An Index of Prognostication

2011 ◽  
Vol 12 (1) ◽  
pp. 24-28 ◽  
Author(s):  
S. Shamshad Ahmad ◽  
Kafil Akhtar ◽  
A.K. Verma ◽  
Amjad Zia Mallik ◽  
Shahid Ali Siddiqui
Keyword(s):  
Lymphocyte Count ◽  
Malignant Tumors ◽  
Peripheral Lymphocyte

scholarly journals Peripheral lymphocyte count as a surrogate marker of immune checkpoint inhibitor therapy outcomes in patients with non-small-cell lung cancer

2022 ◽  
Vol 12 (1) ◽  
Author(s):  
Ye Jin Lee ◽  
Young Sik Park ◽  
Hyun Woo Lee ◽  
Tae Yoen Park ◽  
Jung Kyu Lee ◽  
...  
Keyword(s):  
Adverse Events ◽  
Lymphocyte Count ◽  
Unmet Need ◽  
Surrogate Marker ◽  
Progression Free Survival ◽  
Peripheral Lymphocyte ◽  
Post Treatment ◽  
Before And After ◽  
Check Point Inhibitors ◽  
Nsclc Patients

AbstractDegree of expression of programmed death-ligand 1 (PD-L1) is related with Immune check point inhibitors (ICIs) response but it needs sufficient tumor tissue. There is unmet need for easily accessible and prognostic peripheral blood (PB) biomarkers. We investigated the application of serum peripheral lymphocyte count (PLC) as a predictive PB biomarker for ICI response in patients with NSCLC. We conducted a retrospective study and reviewed the patients with NSCLC who were treated with ICIs from April 1, 2016, to March 31, 2019. The PLC before and after 1 month of immunotherapy was collected. We evaluated the association between PLC and progression-free survival (PFS), overall survival (OS) and adverse events. A total of 231 patients were treated with ICIs for NSCLC. The median follow-up period was 4.7 months and the disease progressed in 138 patients (59.7%). Compared with the lowest quartile (Q1: the lowest 25%), the highest quartile (Q4: the highest 25%) of post-treatment PLC showed a significantly higher PFS (HR 0.28, 95% CI 0.16–0.52) and OS (HR 0.35, 95% CI 0.19–0.65) in the adjusted model. An association between adverse events and PLC was not observed. We revealed that an increased pre- and post-treatment PLC was associated with favorable PFS and OS with NSCLC patients treated with ICIs. PLC could be a helpful for ICI responses in NSCLC.

scholarly journals Impact of Peripheral Lymphocyte Count on the Sensitivity of 2 IFN-γ Release Assays, QFT-G and ELISPOT, in Patients with Pulmonary Tuberculosis

2010 ◽  
Vol 49 (17) ◽  
pp. 1849-1855 ◽  
Author(s):  
Kosaku Komiya ◽  
Haruyuki Ariga ◽  
Hideaki Nagai ◽  
Shinji Teramoto ◽  
Atsuyuki Kurashima ◽  
...  
Keyword(s):  
Pulmonary Tuberculosis ◽  
Lymphocyte Count ◽  
Peripheral Lymphocyte ◽  
Ifn Γ

scholarly journals The Peripheral Lymphocyte Count as an Aid in the Clinical Staging of Lung Cancer

1978 ◽  
Vol 187 (3) ◽  
pp. 248-250 ◽  
Author(s):  
SCOTT P. AARONS ◽  
WILLIAM A. ALBANO ◽  
RANDALL E. HARRIS ◽  
CLAUDE H. ORGAN
Keyword(s):  
Lung Cancer ◽  
Lymphocyte Count ◽  
Peripheral Lymphocyte ◽  
Clinical Staging

scholarly journals Antibody Responses and the Effects of Clinical Drugs in COVID-19 Patients

2021 ◽  
Vol 12 ◽  
Author(s):  
Liwen Wei ◽  
Yuqi Shang ◽  
Xi Liu ◽  
Xinghua Li ◽  
Gongqi Chen ◽  
...  
Keyword(s):  
Antibody Titer ◽  
Lymphocyte Count ◽  
Inflammatory Responses ◽  
Peripheral Lymphocyte ◽  
Protein Subunit ◽  
Epidemic Disease ◽  
Specific Antibodies ◽  
Global Epidemic ◽  
Clinical Drugs ◽  
Humoral Responses

The coronavirus disease 2019 (COVID-19) emerged around December 2019 and have become a global epidemic disease currently. Specific antibodies against SAS-COV-2 could be detected in COVID-19 patients’ serum or plasma, but the clinical values of these antibodies as well as the effects of clinical drugs on humoral responses have not been fully demonstrated. In this study, 112 plasma samples were collected from 36 patients diagnosed with laboratory-confirmed COVID-19 in the Fifth Affiliated Hospital of Sun Yat-sen University. The IgG and IgM antibodies against receptor binding domain (RBD) and spike protein subunit 1 (S1) of SAS-COV-2 were detected by ELISA. We found that COVID-19 patients generated specific antibodies against SARS-CoV-2 after infection, and the levels of anti-RBD IgG within 2 to 3 weeks from onset were negatively associated with the time of positive-to-negative conversion of SARS-CoV-2 nucleic acid. Patients with severe symptoms had higher levels of anti-RBD IgG in 2 to 3 weeks from onset. The use of chloroquine did not significantly influence the patients’ antibody titer but reduced C-reaction protein (CRP) level. Using anti-viral drugs (lopinavir/ritonavir or arbidol) reduced antibody titer and peripheral lymphocyte count. While glucocorticoid therapy developed lower levels of peripheral lymphocyte count and higher levels of CRP, lactate dehydrogenase (LDH), α-Hydroxybutyrate dehydrogenase(α-HBDH), total bilirubin (TBIL), direct bilirubin (DBIL). From these results, we suggested that the anti-RBD IgG may provide an early protection of host humoral responses against SAS-COV-2 infection within 2 to 3 weeks from onset, and clinical treatment with different drugs displayed distinct roles in humoral and inflammatory responses.

Sign in / Sign up

Export Citation Format

Share Document